Effective immunotherapy against cancer: A question of overcoming immune suppression and immune escape?

Cancer Immunology, Immunotherapy

Volumn 53, Issue 10, 2004, Pages 879-892

  Malmberg, Karl Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Immune escape; Immune suppression; Immunotherapy; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CANCER VACCINE; FAS LIGAND; GLYCOPROTEIN GP100[209-217]; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; IDIOTYPIC PROTEIN VACCINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; NAKED DNA; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; SELENIUM; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; FAT INTAKE; GENETIC PROCEDURES; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENCE; LYMPHOCYTE CLONE; LYMPHOCYTE COUNT; LYMPHOMA; MELANOMA; MOLECULAR MECHANICS; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR ESCAPE; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENIC VARIATION; ANTIGENS, CD95; ANTIGENS, NEOPLASM; ANTIOXIDANTS; APOPTOSIS; BONE MARROW TRANSPLANTATION; CANCER VACCINES; DISEASE PROGRESSION; FREE RADICALS; HUMANS; IMMUNE TOLERANCE; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MACROPHAGES; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TIME FACTORS; TUMOR ESCAPE;

EID: 4744358192     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0577-x     Document Type: Conference Paper

References (171)

1. Albina JE, Abate JA, Henry WL Jr (1991) Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation: role of IFN-gamma in the induction of the nitric oxide-synthesizing pathway. J Immunol 147:144
2. Allison J, Georgiou HM, Strasser A, Vaux DL (1997) Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci U S A 94:3943
3. Aoe T, Okamoto Y, Saito T (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881
4. Arai H, Gordon D, Nabel EG, Nabel GJ (1997) Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 94:13862
5. Arista MC, Callopoli A, De Franceschi L et al (1994) Flow cytometric study of lymphocyte subsets in patients at different stages of colorectal carcinoma. Dis Colon Rectum 37:S30
6. Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 99:931
7. Babior BM, Kipnes RS, Curnutte JT (1973) Biological defense mechanisms: the production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 52:741
8. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141
9. Beharka A, Redican S, Leka L, Meydani SN (1997) Vitamin E status and immune function. Methods Enzymol 282:247
10. Bendandi M, Gocke CD, Kobrin CB et al (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5:1171
11. Biaglow JE, Mitchell JB, Held K (1992) The importance of peroxide and superoxide in the X-ray response. Int J Radiat Oncol Biol Phys 22:665
12. Biesalski HK (2002) Meat and cancer: meat as a component of a healthy diet. Eur J Clin Nutr 56[Suppl 1]:S2
13. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254
14. Birkeland ML, Johnson P, Trowbridge IS, Pure E (1989) Changes in CD45 isoform expression accompany antigen-induced murine T-cell activation. Proc Natl Acad Sci USA 86:6734
15. Blanchetot C, Tertoolen LG, den Hertog J (2002) Regulation of receptor protein-tyrosine phosphatase alpha by oxidative stress. Embo J 21:493
16. Brentjens RJ, Latouche JB, Santos E et al (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279
17. Burnet FM (1957) Cancer - a biological approach. BMJ i:841
18. Burnet FM (1970) The concept of immunologicaI surveillance. Prog Exp Tumor Res 13:1
19. Caselli A, Marzocchini R, Camici G et al (1998) The inactivation mechanism of low molecular weight phosphotyrosine-protein phosphatase by H2O2. J Biol Chem 273:32554
20. Cemerski S, van Meerwijk JP, Romagnoli P (2003) Oxidative-stress-induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules. Eur J Immunol 33:2178
21. Childs R, Chernoff A, Contentin N et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750
22. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI (1999) Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 163:507
23. Colonna M, Samaridis J, Cella M et al (1998) Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 160:3096
24. Davidson WF, Giese T, Fredrickson TN (1998) Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 187:1825
25. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M (1997) Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 27:1229
26. DeFrancesco L (2001) Prostate cancer prevention trial launched. Nat Med 7:1076
27. Devadas S, Zaritskaya L, Rhee SG, Oberley L, Williams MS (2002) Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. J Exp Med 195:59
28. Dianzani U, Luqman M, Rojo J et al (1990) Molecular associations on the T cell surface correlate with immunological memory. Eur J Immunol 20:2249
29. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190:1025
30. Dornan S, Sebestyen Z, Gamble J et al (2002) Differential association of CD45 isoforms with CD4 and CD8 regulates the actions of specific pools of p561ck tyrosine kinase in T cell antigen receptor signal transduction. J Biol Chem 277:1912
31. Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850
32. Dummer W, Niethammer AG, Baccala R et al (2002) T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 110:185
33. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991
34. Dutoit V, Taub RN, Papadopoulos KP et al (2002) Multi-epitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110:1813
35. Eaton JD, Perry MJ, Nicholson S et al (2002) Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 89:19
36. Edinger M, Hoffmann P, Ermann J et al (2003) CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9:1144
37. Ehrlich P (1909) Ueber den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 5
38. Engleman EG (2003) Dendritic cell-based cancer immunotherapy. Semin Oncol 30:23
39. Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B (2000) Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 164:5023
40. Fontana A, Frei K, Bodmer S et al (1989) Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 143:3230
41. Fournel S, Aguerre-Girr M, Huc X et al (2000) Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 164:6100
42. Fruh K, Ahn K, Djaballah H et al (1995) A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415
43. Gackowski D, Banaszkiewicz Z, Rozalski R, Jawien A, Olinski R (2002) Persistent oxidative stress in colorectal carcinoma patients. Int J Cancer 101:395
44. Garrido F, Festenstein H, Schirrmacher V (1976) Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature 261:705
45. Garrido F, Ruiz-Cabello F, Cabrera T et al (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89
46. Gaschen B, Taylor J, Yusim K et al (2002) Diversity considerations in HIV-1 vaccine selection. Science 296:2354
47. Gilboa E (1999) The makings of a tumor rejection antigen. Immunity 11:263
48. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52:6949
49. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189
50. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734
51. Gross L (1943) Intradermal immunisation of C3H mice against a sarcoma that origintated in an animal of the same line. Cancer Res 3:326
52. Hahne M, Rimoldi D, Schroter M et al (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363
53. Heinonen OP, Albanes D, Virtamo J et al (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440
54. Hellstrand K, Hermodsson S (1986) Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol 137:656
55. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG (2000) Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 82:1009
56. Hersey P, Zhang XD (2001) How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 1:142
57. Heslop HE, Ng CY, Li C et al (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551
58. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357
59. Ibrahim EC, Guerra N, Lacombe MJ et al (2001) Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61:6838
60. Ikeda H, Lethe B, Lehmann F et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199
61. Jin YJ, Friedman J, Burakoff SJ (1998) Regulation of tyrosine phosphorylation in isolated T cell membrane by inhibition of protein tyrosine phosphatases. J Immunol 161:1743
62. Kambayashi T, Michaelsson J, Fahlen L et al (2001) Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro. Eur J Immunol 31:869
63. Kandil A, Bazarbashi S, Mourad WA (2001) The correlation of Epstein-Barr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing Hodgkin disease. Cancer 91:1957
64. Kemp RA, Ronchese F (2001) Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 167:6497
65. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999
66. Kiessling R, Wasserman K, Horiguchi S et al (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353
67. Kirchner H, Chused TM, Herberman RB, Holden HT, Lavrin DH (1974) Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med 139:1473
68. Klein G (1973) Immunological surveillance against neoplasia. Harvey Lect 69:71-102
69. Koh CY, Blazar BR, George T et al (2001) Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97:3132
70. Koike M, Sekigawa I, Okada M et al (2002) Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res 26:705
71. Kolenko V, Wang Q, Riedy MC et al (1997) Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 159:3057
72. Kono K, Ressing ME, Brandt RM et al (1996) Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2:1825
73. Kono K, Salazar-Onfray F, Petersson M et al (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308
74. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS (1997) Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266
75. Lanier LL (1998) NK cell receptors. Annu Rev Immunol 16:359
76. Leek RD, Harris AL, Lewis CE (1994) Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol 56:423
77. Lefebvre S, Antoine M, Uzan S et al (2002) Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196:266
78. Lehmann F, Marchand M, Hainaut P et al (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340
79. Leitenberg D, Boutin Y, Lu DD, Bottomly K (1999) Biochemical association of CD45 with the T cell receptor complex: regulation by CD45 isoform and during T cell activation. Immunity 10:701
80. Leitenberg D, Novak TJ, Farber D, Smith BR, Bottomly K (1996) The extracellular domain of CD45 controls association with the CD4-T cell receptor complex and the response to antigen-specific stimulation. J Exp Med 183:249
81. Levitskaya J, Coram M, Levitsky V et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685
82. Liang B, Chung S, Araghiniknam M, Lane LC, Watson RR (1996) Vitamins and immunomodulation in AIDS. Nutrition 12:1
83. Liebler DC (1993) The role of metabolism in the antioxidant function of vitamin E. Crit Rev Toxicol 23:147
84. Lin MT, Tseng LH, Frangoul H et al (2000) Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation. Blood 95:3832
85. Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756
86. Ljunggren HG, Karre K (1990) In search of the 'missing self': MHC molecules and NK cell recognition [see comments]. Immunol Today 11:237
87. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS (1999) Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expressiort and proliferation of autologous T cells. J Immunol 163:6251
88. Long EO, Rajagopalan S (2002) Stress signals activate natural killer cells. J Exp Med 196:1399
89. Malmberg KJ, Arulampalam V, Ichihara F et al (2001) Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol 167:2595
90. Malmberg KJ, Lenkei R, Petersson M et al (2002) A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer. Clin Cancer Res 8:1772
91. Malmberg KJ, Levitsky V, Norell H et al (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110:1515
92. Marincola FM, Shamamian P, Simonis TB et al (1994) Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emph Tumor Immunol 16:13
93. Marrack P, Bender J, Hildeman D et al (2000) Homeostasis of alpha beta TCR+ T cells. Nat Immunol 1:107
94. Matsuda M, Petersson M, Lenkei R et al (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61:765
95. Medema JP, de Jong J, Peltenburg LT et al (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98:11515
96. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R (1999) Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190:1033
97. Medema JP, Schuurhuis DH, Rea D et al (2001) Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 194:657
98. Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R (2002) Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 188:177
99. Meydani SN, Meydani M, Blumberg JB et al (1997) Vitamin E supplementation and in vivo immune response in healthy elderly subjects: a randomized controlled trial. JAMA 277:1380
100. Michaelsson J, Teixeira De Matos C, Achour A, Lanier LL, Karre K, Soderstrom K (2002) A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 196:1403
101. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795
102. Mizutani H, Tada-Oikawa S, Hiraku Y, Oikawa S, Kojima M, Kawanishi S (2002) Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide. J Biol Chem 277:30684
103. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248:1230
104. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA (1998) Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160:643
105. Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ (1997) T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40:113
106. Naito Y, Saito K, Shiiba K et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491
107. Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328
108. Novak TJ, Farber D, Leitenberg D, Hong SC, Johnson P, Bottomly K (1994) Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity 1:109
109. Odeleye OE, Watson RR (1991) The potential role of vitamin E in the treatment of immunologic abnormalities during acquired immune deficiency syndrome. Prog Food Nutr Sci 15:1
110. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693
111. Paul P, Cabestre FA, Le Gal FA et al (1999) Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 59:1954
112. Pawelec G, Barnett Y, Forsey R et al (2002) T cells and aging, January 2002 update. Front Biosci 7:d1056
113. Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J (2000) Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog 11:97
114. Pericle F, Kirken RA, Bronte V, Sconocchia G, DaSilva L, Segal DM (1997) Immunocompromised tumor-bearing mice show a selective loss of STATSa/b expression in T and B lymphocytes. J Immunol 159:2580
115. Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137
116. Pisa P, Halapi E, Pisa EK et al (1992) Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A 89:7708
117. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 101:2579
118. Ramal LM, Maleno I, Cabrera T et al (2000) Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 61:1001
119. Restifo NP (2000) Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6:493
120. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100
121. Reth M (2002) Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 3:1129
122. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68
123. Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281
124. Rosenberg SA, Yang JC, Schwartzentruber DJ et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
125. Rosenberg SA, Yang JC, Topalian SL et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907
126. Rosenberg SA, Yang JC, White DE, Steinberg SM (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228:307
127. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK (2002) Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99:2009
128. Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097
129. Rygaard J, Povlsen CO (1974) The mouse mutant nude does not develop spontaneous tumours: an argument against immunological surveillance. Acta Pathol Microbiol Scand [B] Microbiol Immunol 82:99
130. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151
131. Salazar-Onfray F, Charo J, Petersson M et al (1997) Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 159:3195
132. Salvadori S, Martinelli G, Zier K (2000) Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164:2214
133. Santin AD, Hermonat PL, Ravaggi A et al (2001) Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 51:254
134. Schmidt KN, Amstad P, Cerutti P, Baeuerle PA (1996) Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappa B. Adv Exp Med Biol 387:63
135. Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61:4756
136. Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. Embo J 10:2247
137. Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305-334
138. Seaman WE, Gindhart TD, Blackman MA, Dalal B, Talal N, Werb Z (1981) Natural killing of tumor cells by human peripheral blood cells: suppression of killing in vitro by tumor-promoting phorbol diesters. J Clin Invest 67:1324
139. Seliger B, Maeurer MJ, Ferrone S (1997) TAP off-tumors on. Immunol Today 18:292
140. Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455
141. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211
142. Shin MS, Park WS, Kim SY et al (1999) Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 154:1785
143. Shlomchik WD, Couzens MS, Tang CB et al (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:412
144. Spaggiari GM, Contini P, Dondero A et al (2002) Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 100:4098
145. Stutman O (1974) Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183:534
146. Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51:794
147. Takeda K, Hayakawa Y, Smyth MJ et al (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94
148. Tanaka J, Fujiwara H, Torisu M (1979) Vitamin E and immune response, I: enhancement of helper T cell activity by dietary supplementation of vitamin E in mice. Immunology 38:727
149. Teshima T, Mach N, Hill GR et al (2001) Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 61:162
150. Thomas L (1959) Cellular and humoral aspects of the hypersensitive states. Hoeber-Harper, New York
151. Thurner B, Haendle I, Roder C et al (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669
152. Timmerman JM, Singh G, Hermanson G et al (2002) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62:5845
153. Toes RE, Hoeben RC, van der Voort EI et al (1997) Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci U S A 94:14660
154. Trapani JA, Sutton VR, Smyth MJ (1999) CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today 20:351
155. Trowbridge IS, Thomas ML (1994) CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 12:85
156. Turley SJ (2002) Dendritic cells: inciting and inhibiting autoimmunity. Curr Opin Immunol 14:765
157. Urban JL, Holland JM, Kripke ML, Schreiber H (1982) Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J Exp Med 156:1025
158. Uyttenhove C, Van Snick J, Boon T (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815, I: rejection by syngeneic mice. J Exp Med 152:1175
159. Uzzo RG, Clark PE, Rayman P et al (1999) Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 91:718
160. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL (1999) Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. Embo J 18:4250
161. Van der Bruggen P, Traversari C, Chomez P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643
162. Van Pel A, Boon T (1982) Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A 79:4718
163. Vaux DL (1995) Immunology: ways around rejection. Nature 377:576
164. Wang RF (2002) Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 188:65
165. Woo EY, Chu CS, Goletz TJ et al (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766
166. Xu Z, Weiss A (2002) Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol 3:764
167. Yamagishi H, Pellis NR, Macek C, Kahan BD (1980) Changes in spleen morphology and lymphoid cell activity during tumor progression. Eur J Cancer 16:1417
168. Yee C, Thompson JA, Byrd D et al (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99:16168
169. Yewdell JW, Hill AB (2002) Viral interference with antigen presentation. Nat Immunol 3:1019
170. Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP (1999) Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 162:3273
171. Zinkernagel RM (2001) Immunity against solid tumors? Int J Cancer 93:1